Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), also known as CD152, is a cell surface glycoprotein belonging to the immunoglobulin family with a role in regulation of T cell activation (1). Human CTLA-4 is a 223 amino acid (aa) protein with a theoretical molecular weight of 24.6 kDa containing a leader peptide, a IgV-like domain, a transmembrane domain, and a cytoplasmic tail (1,2). CTLA-4 is both structurally and functionally related with another member of the immunoglobulin-related receptor family, CD28 (1-3). CTLA-4 and CD28 receptors are both expressed by CD4+ and CD8+ T cells and share two common ligands, CD80 (B7.1) and CD86 (B7.2), expressed on the surface of antigen presenting cells (APCs) (2,3). While CD28 is present on the plasma membrane of T cells, CTLA-4 is predominantly expressed intracellularly on vesicles in FoxP3+ regulatory T (Treg) cells and activated T cells due to endocytosis (3). While they share ligands, the two receptors have opposing functions in T cell activation; CD28 is involved in activation of T cells, while CTLA-4 functions as a negative regulator of T cell response (2,3). One of the primary functions of CTLA-4 is preventing autoimmunity (1-4).

Similar to programmed cell death protein 1 (PD-1), CTLA-4 is an inhibitory immune checkpoint protein (3,5). Checkpoint blockade immunotherapy using drugs or antibodies to target CTLA-4 is one of the main approaches for cancer treatment (5). A number of drugs targeting CTLA-4, or a combination of CTLA-4/PD-1, have been approved for treatment of various cancers like melanoma, renal cell carcinoma, and colorectal cancer (5). While blocking CTLA-4 in the tumor microenvironment is a promising cancer therapeutic, the absence of CTLA-4 under normal conditions can have deleterious effects. Studies have found that patients with CTLA-4 deficiency or mutations have clinical features associated with autoimmunity and immune dysregulation (4). Treatment options for CTLA-4 deficiency includes immunoglobulin-replacement therapy, corticosteroids, CTLA-4-immunoglobulin (Ig) fusion protein, and, in life-threatening cases, hematopoietic stem cell transplantation (4,6). Additionally, engaging CD80/CD86 with CTLA-4-Ig is a common immunosuppressive treatment for rheumatoid arthritis and kidney transplant recipients (6).

References

1. Romo-Tena, J., Gomez-Martin, D., & Alcocer-Varela, J. (2013). CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance. Autoimmunity reviews, 12(12), 1171-1176. https://doi.org/10.1016/j.autrev.2013.07.002

2. Hosseini, A., Gharibi, T., Marofi, F., Babaloo, Z., & Baradaran, B. (2020). CTLA-4: From mechanism to autoimmune therapy. International immunopharmacology, 80, 106221. https://doi.org/10.1016/j.intimp.2020.106221

3. Rowshanravan, B., Halliday, N., & Sansom, D. M. (2018). CTLA-4: a moving target in immunotherapy. Blood, 131(1), 58-67. https://doi.org/10.1182/blood-2017-06-741033

4. Verma, N., Burns, S. O., Walker, L., & Sansom, D. M. (2017). Immune deficiency and autoimmunity in patients with CTLA-4 (CD152) mutations. Clinical and experimental immunology, 190(1), 1-7. https://doi.org/10.1111/cei.12997

5. Rotte A. (2019). Combination of CTLA-4 and PD-1 blockers for treatment of cancer. Journal of experimental & clinical cancer research : CR, 38(1), 255. https://doi.org/10.1186/s13046-019-1259-z

6. Bluestone, J. A., St Clair, E. W., & Turka, L. A. (2006). CTLA4Ig: bridging the basic immunology with clinical application. Immunity, 24(3), 233-238. https://doi.org/10.1016/j.immuni.2006.03.001

Long Name

Cytotoxic T-lymphocyte-associated Molecule 4

Alternate Names

CD152, CTLA4

Gene Symbol

CTLA4

Additional CTLA-4 Products

Product Documents for CTLA-4 Antibody (Antitope patent anti-CTLA4) [Alexa Fluor® 532]

Product Datasheets

Download Product Datasheets

COA

SDS

Download SDS

Product Specific Notices for CTLA-4 Antibody (Antitope patent anti-CTLA4) [Alexa Fluor® 532]

Alexa Fluor (R) products are provided under an intellectual property license from Life Technologies Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components, or any materials made using the product or its components, in any activity to generate revenue, which may include, but is not limited to use of the product or its components: (i) in manufacturing; (ii) to provide a service, information, or data in return for payment; (iii) for therapeutic, diagnostic or prophylactic purposes; or (iv) for resale, regardless of whether they are resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@lifetech.com. This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Citations
Reviews

Spectra Viewer
Flow Cytometry

CTLA-4 Antibody (Antitope patent anti-CTLA4) [Alexa Fluor® 532]

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28818AF532

Key Product Details

Species Reactivity

Validated:

Applications

Label

Antibody Source

Concentration

View all CTLA-4 Antibodies »

Product Summary for CTLA-4 Antibody (Antitope patent anti-CTLA4) [Alexa Fluor® 532]

Immunogen

Clonality

Host

Isotype

Applications for CTLA-4 Antibody (Antitope patent anti-CTLA4) [Alexa Fluor® 532]

ELISA

Flow Cytometry

Functional

Formulation, Preparation, and Storage

Purification

Formulation

Preservative

Concentration

Shipping

Stability & Storage

Background: CTLA-4